NKTR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...

Stats
Today's Volume	1.14M
Average Volume	2.59M
Market Cap	322.26M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.210
ATR14	$0.00600 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Deep Track Capital, Lp	Sell	56 000	Common Stock
2024-03-05	Deep Track Capital, Lp	Buy	0	Common Stock
2024-02-20	Zalevsky Jonathan	Sell	9 014	Common Stock
2024-02-20	Wilson Mark Andrew	Sell	7 606	Common Stock
2024-02-20	Robin Howard W	Sell	20 033	Common Stock

INSIDER POWER
81.10
Last 97 transactions
Buy: 6 961 163 \| Sell: 693 451

Volume Correlation

Long: 0.45 (neutral)

Short: -0.62 (weak negative)

Signal:(54.774) Neutral

Nektar Therapeutics Correlation

10 Most Positive Correlations
PAYS	0.961
USAP	0.96
SVFAU	0.954
IXAQ	0.953
IVCB	0.953
VCTR	0.951
VITL	0.951
BCSA	0.947
GGAL	0.945
CSLM	0.943

10 Most Negative Correlations
VEEE	-0.954
JACK	-0.948
INTZ	-0.948
HCDIP	-0.946
SIRI	-0.941
ALLR	-0.94
HAIN	-0.934
LCFY	-0.934
SHEN	-0.934
APDN	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nektar Therapeutics Correlation - Currency/Commodity

-0.83
( strong negative )

-0.81
( strong negative )

0.00
( neutral )

-0.62
( weak negative )

Nektar Therapeutics Financials

Annual	2023
Revenue:	$90.12M
Gross Profit:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2023
Revenue:	$90.12M
Gross Profit:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2022
Revenue:	$92.06M
Gross Profit:	$70.42M (76.50 %)
EPS:	$-1.970

FY	2021
Revenue:	$101.91M
Gross Profit:	$77.01M (75.57 %)
EPS:	$-2.86

Financial Reports:

No articles found.

Nektar Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.